This pharmacovigilance analysis identified several drugs disproportionately associated with CTS in the FAERS database, including ERTs, aromatase inhibitors, bisphosphonates, GH-releasing factor analogs, GHB, rofecoxib, and tafamidis. Here, CYP19A1 is linked to carpal tunnel syndrome.